Pirfenidone improves renal function and fibrosis in the post-obstructed kidney

Area of Science:

• Nephrology
• Pharmacology

Background:

• Pirfenidone (PFD) is an anti-fibrotic agent with demonstrated efficacy in preventing and reversing extracellular matrix accumulation.
• Unilateral ureteral obstruction (UUO) serves as a model for experimental renal disease, leading to tubulointerstitial fibrosis.

Purpose of the Study:

• To investigate the effects of PFD on collagen production and renal function in a UUO rat model.
• To assess PFD's potential to attenuate renal fibrosis and damage, and to restore renal function after obstruction release.

Main Methods:

• Rats underwent UUO or sham surgery and were treated with PFD (500 mg/kg/day) for 21 days.
• Renal function (inulin clearance) and collagen content (hydroxyproline) were measured post-obstruction release.
• Gene expression of collagen, matrix metalloproteinase-2, and transforming growth factor-beta (TGF-beta) was analyzed.

Main Results:

• PFD significantly suppressed the increase in kidney collagen content and hydroxyproline levels in UUO rats.
• PFD treatment inhibited the expression of mRNA for type IV and I collagen, matrix metalloproteinase-2, and TGF-beta.
• PFD administration post-obstruction release attenuated collagen accumulation and improved renal function, indicated by increased inulin clearance.

Conclusions:

• PFD effectively attenuates renal fibrosis and damage in the UUO rat model.
• These findings suggest PFD's clinical utility in preventing progressive, irreversible renal failure.